Colchicine-induced leukopenia usually occurrs in intentional or accidental overdoses or inappropriate use in combination with intravenous and oral colchine; however, there have been several reports of hematologic toxicity in short-term and small-dose colchicine medication courses. We present two cases of leukopenia induced by colchicine use concurrent with immunosuppressants in Behçet's disease. We postulate that the mechanism of colchicine-induced leukopenia might be the destruction of circulating leukocytes and an inhibition of leukocyte production by the immediate and direct toxic effect of colchicine on idiosyncrasies unique to each patient. The concurrently administered immunosuppressant might decrease the threshold for hematologic toxicity of colchicine in the leukocytes and their precursor cells.
Key Words: Behçet's disease, colchicine, leukopenia Sir, Behçet's disease (BD) is rec urrent and long standing inflammatory disease whic h is hard to c ontrol in some patients. Colc hic ine appears to be a promising and safe drug for BD with infrequent or minor side effec ts. 1 Common side effec ts of c olc hic ine inc luding diarrhea and gastrointestinal upset are mild and self-limited, however, severe reac tions like leukopenia, aplasticanemia, c onfusion, azoospermia, alopec ia, myopathy and c horea-like syndrome may oc c ur. 2 We present two c ases of ac ute leukopenia after short-term use of c olc hic ine in BD patients who were c onc urrently taking immunosuppresants.
A 58-year-old Korean woman (c ase 1) who had been taking prednisolone and azathioprine for two years and a 71-year-old Korean woman (c ase 2) who had been taking methotrexate for three years. Both of them were diagnosed as inc omplete type BD ac c ording to RCJ Criteria. 3 Oral c olc hic ine (1.2 mg per day) was added to alleviate muc oc utaneous symptoms, and leukopenia was disc overed after adding oral c olc hic ine, on 14th days in the first patient and 3rd days in the sec ond patient. However, blood c ell c ounts of both patients were rec overed after c essation of c olc hine and immunosuppresants with c onservative treatment with G-CSF (Table 1 ). In c ase 2, neither c olc hic ine nor immunosuppresant administered afterward and her symptoms are well c ontrolled only with sulfasalazine, ac ec lofenac and topic al dexaltin c urrently. On the other hand, in c ase 1, prednisolone, analgesic s and azathioprine were restarted 5 months later due to intrac table BD, and regular laboratory studies showed no abnormalities. Uveitis and aphthous ulc er of the patient were not well c ontrolled at that time, so oral c olc hic ine (1.2 mg per day) was added to her regimen again. Ten days after adding c olc hic ine, the patient was readmitted due to septicshoc k and leukopenia and she was died despite intensive c are.
It is assumed that c olc hic ines was c losely related in leukopenia of both patients even though the dose was small and the duration of c olc hic ine use was short. Our patients had rec eived immunosuppressant drugs for a few years without c omplic ations before taking c olc hic ine, and the prompt disc ontinuation of c olc hic ine resulted in rec overy of the leukoc yte c ount in both patients. In addition, the leukopenicevent was repeated after the re-initiation of c olc hic ine therapy in c ase 1.
It is hard to c onc lude that leuc openia was c aused by inhibiting mic rotubule assembly in mitosis by c olc hic ine bec ause the dose of c olc hic ine was too small and leukopenia developed very rapidly after the administration. 2 Bone marrow c ellularities and leukoc yte c ounts were dec reased and leukoc ytes with abnormal morphology appeared in peripheral blood in both of our patients. So the immediate destruc tion of leukoc ytes with an ac c ompanying inhibition of leukoc yte produc tion might have been c aused by the direc t toxiceffec t of c olc hic ines and it c ould be the mec hanism of c olc hic ineinduc ed ac ute leukopenia superimposed on idiosync rasies. Proposed mec hanisms of ac ute c olc hic ine-induc ed leukopenia were dec reased c learanc e of the drug in the patients with underlying hepatic or renal dysfunc tion, drug interac tion of c olc hic ine with some drugs whic h inhibit P-glyc oprotein, and c onc urrent viral infec tion. 4, 5 However, our patients did not have any evidenc e of hepaticdysfunc tion, renal dysfunc tion or usage of drugs whic h inhibit P-glyc oprotein. And serologictests for c ytomegalovirus, rubella virus, measles virus, Ebstein-Barr virus, human immunodefic ienc y virus and varic ella zoster virus were negative. We propose that immunosuppresants might dec rease the threshold for the idiosync raticreac tion of c olc hic ine in leukoc ytes and prec ursor c ells. In fac t, it is well known that those c ells whic h are c hronic ally exposed to immunosuppressant are vulnerable to the toxic ity of other drugs and infec tions, and also the c onc entration of c olc hic ine and immunosuppresants of the leukoc ytes and prec ursor c ells are higher than the c onc entration of serum due to muc h slower c learanc e of the c ompound. 6, 7 We share our c ase to highlight c olc hic ines use in the patients taking immunosuppressant c an induc e ac ute leukopenia whic h is ac ute, unpredic table and may be irreversible and life-threatening. We propose that any patient who is treated with c olc hic ine may be at risk of hematologictoxic ity and should be monitored frequently, espec ially in c ase of c onc urrently using immunosuppressants as well as other drugs known to have interac tions with c olc hic ine. In addition, prompt administration of G-CSF must be c onsidered in the patient with c olc hic ine-induc ed leukopenia, bec ause the administration of G-CSF is known to be very useful and effec tive treatment regardless of whether c olc hic ineinduc ed leukopenia is c aused by overdose or long-term treatment or an idiosync raticreac tion. 8, 9 
